You have to look at what Antares brings to the table & what a potential partner risks.
" Antares is responsible for research and development activities as they relate to ATD formulation and manufacturing, using the Population Council’s patented and other proprietary information covering the compound. The Population Council is responsible for research on Nestorone and clinical trial design development and management. "
Antares has really not expended a large amount of resources at this point. A partner would be foolish to take on all the risk & sign away more then 10 - 12% of the royalty income. If Antares wants to partner Nestragel then I expect them to fund a portion of the trials.
Wotten's main focus is on the internal injector program's development. He's stated that this is whats going to take Antares to the next level. When he made the statement about partnering I don't believe it necessarily pertained to Nestragel.